Business Context and Reporting Period
This Form 8-K was filed by Pavmed Inc. on October 18, 2021. The report details a significant corporate transaction involving the company's majority-owned subsidiary, Lucid Diagnostics Inc. ("Lucid"), which completed its initial public offering (IPO) on this date.
Key Financial Metrics and Transaction Details
- Investment in Subsidiary: Pavmed purchased 571,428 shares of Lucid common stock in the IPO at a price of $14.00 per share.
- Cash Outlay: The aggregate cash purchase price was approximately $8.0 million.
- Debt Conversion: Prior to the IPO, on October 13, 2021, a promissory note held by Pavmed with a principal amount of $22.4 million was converted into 15,803,200 shares of Lucid common stock.
- Ownership Stake: Following the IPO and debt conversion, Pavmed owns approximately 75.5% of Lucid's outstanding common stock.
Note: This filing does not provide consolidated revenue, profit, cash flow, or margin data for Pavmed Inc. for a specific reporting period.
Material Changes
The primary material change reported is the monetization of a portion of Pavmed's debt exposure in Lucid into equity and the strategic decision to invest additional cash to maintain a controlling interest. The conversion of the $22.4 million promissory note eliminated this specific debt obligation in exchange for a significant equity position.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard disclosure of the transaction itself. The document focuses strictly on the completion of the asset acquisition (purchase of shares) and the resulting ownership structure.
Key Facts for Investor Verification
- Verify the current market price of Lucid Diagnostics (LUCD) to assess the unrealized gain or loss on the 571,428 shares purchased at $14.00.
- Confirm the total number of outstanding shares for Lucid to validate the 75.5% ownership calculation.
- Review Pavmed's subsequent financial statements to determine the impact of the $8.0 million cash outflow on liquidity.
- Check for any subsequent filings regarding the valuation of the remaining 24.5% of Lucid not owned by Pavmed.